Loading
Latest filing published 27 Jun 2025 for Regulus Therapeutics Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Christopher Ray Aker is a declared insider of Regulus Therapeutics Inc. (board member), with filings sourced from SEC (Form 4). The record holds 6 filings, for trades running from 17 May 2021 to 25 June 2025.
Sales make up the whole of the open-market record (3 sales, €54k). The rest of the record consists of 2 share grants. 2025 to date brings no purchases and 1 sale.
On 27 June 2025 came the latest disclosure, a transaction in Regulus Therapeutics Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations